CASE REPORT OF BELL’S PALSY FOLLOWING SECOND DOSE OF COVISHIELD VACCINE

Authors

  • NAGMA BANSAL Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.
  • SULENA SULENA Department of Neurology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.
  • RAJ KUMAR Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.
  • MAMATA SINGH Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.
  • AMANDEEP KAUR Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i7.44844

Keywords:

Bell's palsy, Covishield, ChAdOx1 nCoV-19, Adverse event, pharmacovigilance, Covid Immunization

Abstract

Bell’s palsy, also known as acute peripheral facial palsy of unidentified reason, is caused by the acute onset of problems with the facial nerve’s lower motor neuron. Several case reports and series have described peripheral facial nerve palsy associated with COVID-19. In addition, since the US food and drug administration’s (FDA) emergency use authorization of several COVID-19 vaccines, there have been media reports of Bell’s palsy associated with vaccination. This case concerns a 26-year-old female with Bell’s palsy (confirmed by clinical diagnosis – an acute unilateral facial nerve paresis or paralysis with onset in >72 h) after receiving second dose of Covishield vaccine (ChAdOx1 nCoV-19). She experienced decreased sleep, dizziness, and left side eye watering post-vaccination. Next day after vaccination, she noticed muscle weakness on the left side of the face, preventing her from close left eye, drinking fluids, and facial droop accompanied by reduced mobility. The patient was treated with methylprednisolone and eye drops (lubricants).

Downloads

Download data is not yet available.

Author Biographies

NAGMA BANSAL, Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.

Senior Resident, Deptt. Pharmacology, Govt. GGS Medical College (BFUHS), Faridkot, Punjab, India 

SULENA SULENA, Department of Neurology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.

Associate Professor, Dept. Neurology, GGS Medical College (BFUHS), Farikdot, Punjab

RAJ KUMAR, Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.

Deptt. of Pharmacology

Associate Professor

MAMATA SINGH, Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.

Resident, Deptt. Pharmacology, GGS Medical College (BFUHS), Faridkot, Punjab

AMANDEEP KAUR, Department of Pharmacology, Guru Gobind Singh Medical College and Hospital (Baba Farid University of Health Sciences), Faridkot, Punjab, India.

Techanical Associate Pharmacovigilance, Dept. Pharmacology, GGS Medical College, Faridkot.

References

Yoo MC, Soh Y, Chon J, Lee JH, Jung J, Kim SS, et al. Evaluation of factors associated with favorable outcomes in adults with Bell palsy. JAMA Otolaryngol Head Neck Surg 2020;146:256-63. doi: 10.1001/ jamaoto.2019.4312, PMID 31971554

Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. J Oral Pathol Med 2021;50:424-7. doi: 10.1111/jop.13165, PMID 33527524

Wan EY, Chui CS, Lai FT, Chan EW, Li X, Yan VK, et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: A case series and nested case-control study. Lancet Infect Dis 2022;22:64-72. doi: 10.1016/S1473- 3099(21)00451-5, PMID 34411532

Ministry of Health and Family welfare. About the Vaccine. Government of India: Ministry of Health and Family welfare; 2022. Available from: https://www.mohfw.gov.in/covid_vaccination/vaccination/faqs. html#about-the-vaccine [Last assessed on 2022 Mar 14].

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij- Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78. doi: 10.1016/S0140-6736(20)31604-4, PMID 32702298

Fidler S, Stöhr W, Pace M, Dorrell L, Lever A, Pett S, et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): A phase 2, randomised trial. Lancet 2020;395:888-98. doi: 10.1016/S0140-6736(19)32990-3, PMID 32085823

Hanke T. Aiming for protective T-cell responses: A focus on the first generation conserved-region HIV consv vaccines in preventive and therapeutic clinical trials. Expert Rev Vaccines 2019;18:1029-41. doi: 10.1080/14760584.2019.1675518, PMID 31613649

Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, et al. Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). EClinicalMedicine 2019;11:65-80. doi: 10.1016/j. eclinm.2019.05.009, PMID 31312806

Fact Sheet for Vaccine Recipient Approved for Restricted Use in Emergency Situation of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant); 2022. Available from: https://www. seruminstitute.com/pdf/covishield_fact_sheet.pdf [Last assessed on 2022 Mar 12].

Fact Sheet for Vaccine Recipients and Caregivers Restricted Use in Emergency Situation of Covid-19 Covaxin SARS-CoV-2 Vaccine by Bharat Biotech. Available from: https://www.bharatbiotech. com/images/covaxin/covaxin-factsheet.pdf [Last assessed on 2022 Mar 11].

Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical practice guideline: Bell’s palsy. Otolaryngol Head Neck Surg 2013;149:S1-27. doi: 10.1177/0194599813505967, PMID 24189771

Published

07-07-2022

How to Cite

BANSAL, N., S. SULENA, R. KUMAR, M. SINGH, and A. KAUR. “CASE REPORT OF BELL’S PALSY FOLLOWING SECOND DOSE OF COVISHIELD VACCINE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 7, July 2022, pp. 1-2, doi:10.22159/ajpcr.2022.v15i7.44844.

Issue

Section

Case Study(s)